In high-throughput biochemical assays performed in multiwell plates, the effect of test samples on the activity of the biochemical system is usually measured by optical means such as absorbance, fluorescence, luminescence, or scintillation counting. The test sample often causes detection interference when it remains in the well during the measurement. Interference may be due to light absorption, fluorescence quenching, sample fluorescence, chemical interaction of the sample with a detection reagent, or depression of the meniscus. A simple method is described that corrects for such interference well by well. The interference is measured in a separate artifact assay plate. An appropriate arithmetic correction is then applied to the measurement in the corresponding well of the activity assay plate. The correction procedure can be used for single-point screening or potency measurements on serial dilutions of test samples. same as the uninhibited reaction. It will be falsely concluded that the sample is not inhibitory. In another example, if an uninhibited enzyme reaction causes the absorbance to decrease by 0.2 units, a noninhibitory test sample with an absorbance of 0.1 will result in a measured absorbance change of 0.1 units, representing 50% inhibition, a false positive. The extinction coefficient required for a test sample at 10 µM to produce an absorbance of 0.1 units for a typical path length of 5 mm in a 384-well assay plate is an unexceptional 20 mM -1 ⋅cm -1 . The problem of light absorption by test samples is not limited to absorbance-based assays. In fluorescence-based assays, absorption of the excitation and/or emission light by the test sample is equally problematic, as is the absorption of the emitted light in scintillation-and luminescence-based assays. Reducing the assay volume to minimize the path length through which the light travels can reduce absorption effects in fluorescence and luminescence assays. In bead-based scintillation and luminescence assays, floating the beads on the surface prior to measurement can achieve the same effect. Also, because the magnitude of interference caused by test samples tends to decrease as the monitored wavelength increases, assays monitoring long wavelengths are prone to less interference than those monitoring shorter wavelengths.
INTRODUCTION

H
igh-throughput screening of large collections of chemical compounds and extracts is widely used, both in the pharmaceutical industry and academia, to identify starting points for pharmaceutical drug and chemical genetics discovery programs, respectively. Biochemical screens typically involve measuring the inhibitory or stimulatory effect of each test compound, pool of compounds, or extract on a biochemical assay system, such as the catalytic activity of an enzyme or binding of a ligand to a receptor. The readout of the assay is usually an optical measurement such as absorbance, fluorescence, luminescence, or scintillation counting carried out in the wells of multiwell plates. Assays in which all the components are added serially to the wells, without any filtration or washing steps, are desirable because of their speed, simplicity, and ease of automation. A drawback of such "add-only" assays, however, is that the test sample remains in the well during the optical measurement and can interfere with it. We describe below the nature of compound interference that can occur with several commonly used high-throughput assay detection methods.
Interference by absorption of light
Most of the organic compounds in pharmaceutical company compound collections contain aromatic rings, resulting in UV absorbance in the 200-to 300-nm range of the spectrum. Many compounds also have absorbance in the near UV and violet range (300-450 nm). In addition, aging of test samples sometimes results in the formation of strongly absorbing substances, even in the visible range (400-700 nm). Some libraries also contain colored compounds and extracts. A typical circumstance in high-throughput screening (HTS) using absorbance-based assays used by us is an assay volume of 30 to 60 µL in the well of a 384-well assay plate, with a test compound present at 10 µM. In some cases, the compound concentration may be much higher. In so-called fragment-based lead generation, we have conducted enzyme assays with small test compounds (molecular weight ≤300) at concentrations up to 2 mM. 1 Also, mixtures of test samples may sometimes be placed in each well. It is therefore inevitable that some of the test samples will have significant absorbance at the wavelength(s) of light monitored in the assay used for screening or measurement of potency.
In the assay, absorption of light by the test sample, if significant, will result in a false estimate of the potency of the sample. For example, if an uninhibited enzyme reaction causes the absorbance to increase by 0.2 units and the test sample inhibits the reaction by 50%, the final absorbance will increase by 0.1 units when the test sample is present and has no absorbance of its own. If, however, the sample has an absorbance of 0.1 units, the final absorbance change will be 0.2 units, the same as the uninhibited reaction. It will be falsely concluded that the sample is not inhibitory. In another example, if an uninhibited enzyme reaction causes the absorbance to decrease by 0.2 units, a noninhibitory test sample with an absorbance of 0.1 will result in a measured absorbance change of 0.1 units, representing 50% inhibition, a false positive. The extinction coefficient required for a test sample at 10 µM to produce an absorbance of 0.1 units for a typical path length of 5 mm in a 384-well assay plate is an unexceptional 20 mM
The problem of light absorption by test samples is not limited to absorbance-based assays. In fluorescence-based assays, absorption of the excitation and/or emission light by the test sample is equally problematic, as is the absorption of the emitted light in scintillation-and luminescence-based assays. Reducing the assay volume to minimize the path length through which the light travels can reduce absorption effects in fluorescence and luminescence assays. In bead-based scintillation and luminescence assays, floating the beads on the surface prior to measurement can achieve the same effect. Also, because the magnitude of interference caused by test samples tends to decrease as the monitored wavelength increases, assays monitoring long wavelengths are prone to less interference than those monitoring shorter wavelengths.
Quenching of fluorescence and luminescence
Fluorescence-and luminescence-based assays are widely used because of their sensitivity, which allows miniaturization, such as to a 1536-well format. Miniaturization greatly reduces the effect of light absorption (see above) but does not reduce interference caused by quenching of the excited state of the reporter by the test sample, so that light is not emitted. In an assay in which the biochemical activity is monitored by an increase in fluorescence intensity or luminescence, quenching by the test sample causes it to appear to have greater potency. Conversely, in an assay in which the biochemical potency is monitored by a decrease in fluorescence intensity or luminescence, quenching by the test sample causes it to appear to have lower potency.
Fluorescent test samples
Test samples are frequently observed to have fluorescence of their own. 2 The interference caused by this fluorescence in fluorescence intensity-based assays acts analogously to absorption of light in absorbance-based assays by causing a misleading measurement of test sample potency. In rare instances, test samples may also exhibit chemiluminescence, causing an interfering signal in luminescence-and scintillation-based assays.
Some fluorescence-based assays use ratiometric readouts. A fluorescence resonance energy transfer (FRET)-based assay might measure the ratio of fluorescence at the 2 emission wavelengths of the FRET donor and acceptor. Test sample fluorescence is likely to differ at the 2 wavelengths. Also, the extent of quenching of the fluorescence of the donor and acceptor by the test sample may differ. The test sample may also absorb light. Therefore, the effect of interference by the test sample on the potency measurement may be unpredictable.
A fluorescence polarization (FP) (or anisotropy)-based assay combines the intensity of fluorescence emission at orthogonal polarizer angles. In addition to the types of interference already described, the fluorescence of a test sample will have its own characteristic polarization, which will contribute to the measured polarization and thus interfere with the measurement of the potency of the test sample. A further means by which a test sample may interfere in an FP assay is by light scattering. Turbidity due to insolubility of the test sample could result in detection of highly polarized scattered light. Interference in FP assays can be reduced by using longer wavelength fluorophores or increasing the fluorophore concentration. 3 Interference with detection reagents. In some assays, detection of the product is indirect, requiring, for example, a chemical reaction with a special reagent. Examples are the detection of free thiols by Ellman's reagent to produce a yellow product, 4 the detection of inorganic phosphate by the malachite green/ molybdate reagent 5 to generate an absorbance increase, and the chemiluminescent detection of adenosine triphosphate (ATP) by the luciferin/luciferase reaction. 6 In addition to the types of interference previously described, the test samples can reduce the sensitivity of the detection reaction for the product by interacting with it in a nonproductive way or create a falsely high signal by reacting with the detection reagent in a productive way. As an example, Auld et al. 7 found that 0.9% of the test samples in a 70,000-sample screening library inhibited Photinus pyralis luciferase by at least 50% at concentrations less than 10 µM, which would result in at least 9000 false positives in a luciferase-based screen of a 1,000,000-sample library.
Meniscus effects
Test substances can cause a deepening of the meniscus of the liquid in the well of a multiwell plate because of surfactantlike physical properties. Light absorption-based assays measure the attenuation of light through the liquid column. Increasing the depth of the meniscus decreases the path length and thereby decreases the absorbance. In fluorescence-and luminescence-based assays, increasing the meniscus depth can reduce the amount of light collected from top-reading instruments. Meniscus depression should therefore be treated as a form of signal attenuation.
The types of interference described above are widely recognized, and strategies to minimize interference previously have been discussed by Imbert et al. 8 There have been few attempts, however, to systematically measure and correct for samplebased interference. In this article, we first give examples of how this type of optical interference affected the measurement of the potency of test samples identified in high-throughput screens (see also Inglese et al. 9 ). We then describe a simple arithmetic procedure to correct the potency measurement for interference and show how it improves the accuracy of the measurements.
MATERIALS AND METHODS
Correcting for interference by test samples
Our approach to dealing with the problem of interference in optical assays by test samples is to measure the extent of the interference separately from the activity assay and then apply an arithmetic correction to the activity assay readout based on the measured interference. For each multiwell plate of test samples used in the activity assay, a separate plate is prepared containing the same arrangement of test samples for use in this so-called artifact assay. The artifact assay plate also contains wells with no test sample, used to establish the baseline (B1; Fig. 1 ). Because it is necessary to measure an increase or a decrease in the baseline signal due to the presence of the test sample, each well in the artifact assay plate, including those with no test sample, must also contain some of the substance responsible for generating the signal, typically the product of the reaction used in the assay, preferably in an amount similar to that produced in the activity assay.
Increases and decreases from the baseline in the artifact assay plate caused by the presence of the test sample are handled
FIG. 1.
An example of the arrangement of samples in the activity assay and artifact assay plates. In the activity assay plate, full-activity and no-activity control wells are in columns 1 and 12, and test sample dilutions are in columns 2 to 11. The no-activity control wells are used as the baseline for the activity assay plate. In the artifact assay plate, the test sample dilutions are arranged the same way as in the activity assay plate, and columns 1 and 12 contain no test sample. The product that is detected by the assay is added equally to all wells in the artifact assay plate. The measurements in columns 1 and 12 of the artifact assay plate are used as the baseline for the artifact assay. In this example, row B contains a test sample that adds to the signal, and row F contains a test sample that reduces the signal. Depth of shading represents extent of product formation in enzyme reaction or extent of binding in ligand-receptor interaction. 
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in different ways ( Table 1) . Typical signal increases are caused by absorbing test samples in absorbance assays, fluorescent test samples in fluorescence intensity assays, or reaction of the test sample with detection reagents. For an increased signal, the excess over the baseline in the artifact assay plate (S1-B1) is simply subtracted from the signal in the corresponding well of the activity assay plate (S2). This is because absorbances and fluorescence intensities of dilute substances in mixtures are usually additive. A decreased signal in the artifact assay plate is considered to be due to a loss of detection sensitivity. Typical signal decreases are caused by absorbing test samples in fluorescence-, luminescence-, or scintillation-based assays; by quenching in fluorescence-or luminescence-based assays; or by nonproductive interference with detection reagents. For a decreased signal, the arithmetic correction of the signal in the assay plate proceeds as follows for each well ( Table 1) : (1) subtract from all measurements in both the activity assay and artifact assay plates any background signal that is not affected by interference. Examples of such background include absorption of light by detection reagents in absorbance assays and background in fluorescence measurements caused by instrument stray light. In many cases, the background is negligible. For the purpose of the following, it is assumed that the background has already been subtracted. (2) Compute the ratio of the measured value in the artifact assay plate well to the baseline: S1/B1. (3) Divide the signal in the activity assay plate by the ratio computed in step (2): S2 × B1/S1. See the Appendix for the justification of a ratiometric correction factor for signal attenuation due to light absorption and quenching in fluorescence intensity-and luminescence-based assays.
For assay types that combine 2 separate measurements, such as FRET and FP, it is necessary to apply the interference correction procedure to the 2 measurements individually, prior to combining them. It would not be accurate to correct the aggregated readout because each of the 2 measurements that are combined may be affected by the interference to different extents or even in opposite ways. For FP assay interference, it would not be safe to assume that the interference with parallel and perpendicular intensities cancel out when the measurements are combined. Interference caused by low-polarization fluorescence will predominantly affect the perpendicular intensity. In contrast, interference caused by high-polarization scattered light from insoluble material or high-polarization fluorescence from aggregated fluorescent material will predominantly affect the parallel intensity.
Although there is no theoretical limit to the extent of interference for which the correction procedure is applicable, signal noise results in a practical limit. The larger the amount of interference relative to the true signal in the assay, the more the noise in the assay signal comes to dominate the outcome of the calculation. The limit to size of the correction factor can be determined by experience with individual assays. Based on our experience with high-throughput assays having Z′ scores of 0.7 to 0.8 and windows of 10 to 20, we recommend, as a rule of thumb, limiting the size of the correction to a factor of 2. An artifact that results in a signal that is more than twice or less than half the baseline in the artifact assay plate results in rejection of the data in the corresponding well of the activity assay plate ( Table 1) .
To avoid introducing bias during the correction procedure, it is important that the signal in the assay, including the interference, should remain within the linear range of detection of the assay, unless a detection standard is used to convert a nonlinear measurement to product quantity. In that case, the conversion should be applied prior to the correction procedure.
RESULTS
Examples of assay detection interference by test samples
Data from high-throughput screens conducted at AstraZeneca are described below as examples of different commonly used detection technologies and the extent to which they are prone to interference by test samples.
In the first example, a high-throughput screen used scintillation proximity assay technology 10 to measure binding of a tritiated radioligand to a biotinylated receptor that was in turn bound to streptavidin-coated scintillant beads. The beads were allowed to settle to the bottom of the wells before measurement. Test samples showing apparent inhibition of binding when screened at 10 µM were subjected to an artifact assay, in which tritiated biotin was used to generate a signal in the absence of the ligand and receptor. The distribution of the concentrations of the samples required to give 50% inhibition of the signal in this artifact assay is shown in Figure 2 . Of the 1412 samples tested, 656 (46%) reduced the signal by 50% at 50 µM or less, demonstrating a high potential rate of false positives for the screen. This was most likely the result of test sample absorption of the short-wavelength light emitted by the scintillant beads.
Another high-throughput screen used the increase in fluorescence intensity, with excitation at 485 nm and emission at 
None Reject data B1, baseline in artifact assay plate; S1, signal in test well of artifact assay plate; S2, signal in test well of activity assay plate. It is assumed that any constant background that is not affected by interference would have been subtracted from all measurements in both plates. Data are rejected if the interference results in more than a 2-fold change in signal (see Materials and Methods).
535 nm, to monitor the progress of an enzyme reaction. Test samples showing apparent inhibition of activity when tested at 10 µM were investigated further. Serial dilutions of these samples were then tested in the same assay. At the same time, fluorescence measurements were made with the samples in the absence of the enzyme (S1) and compared to the fluorescence of the substrate as the baseline (B1). The distribution of the percentage difference from the fluorescence baseline of the 10-µM concentration of 1680 samples in the absence of the enzyme is shown in Figure 3 . The distribution is highly skewed toward a reduction of fluorescence by the samples, with 147 (8.8%) causing a decrease of more than 10%. Several effects could have contributed to the reduction of fluorescence, including light absorption, fluorescence quenching, and meniscus depression by the test samples. In a third high-throughput screen, the production of orthophosphate was measured by the increased absorbance of malachite green/molybdate reagent at 650 nm. 5 Test samples showing apparent inhibition of activity when tested at 10 µM were investigated further. Serial dilutions of these samples were then tested in the same assay. At the same time, malachite green/molybdate absorbance measurements were made using a control plate with the samples in the absence of the enzyme (S1) but in the presence of added orthophosphate as a baseline (B1). The orthophosphate concentration used was half the concentration produced by the enzyme reaction in the absence of inhibitor. The distribution of the percentage difference from the orthophosphate baseline of the 10-µM concentration of 1200 samples in the absence of the enzyme is shown in Figure 4 . The distribution is highly skewed toward a reduction of absorbance by the samples, with 382 (31.8%) causing a decrease of more than 10%. This was most likely due to a loss of sensitivity of the malachite green/molybdate reagent's detection of orthophosphate caused by the test samples.
In these examples, the type of interference observed was biased toward causing an apparent increased inhibitory potency of the test samples because the samples tested were selected from among those that appeared to be active in the initial   FIG. 2 . Distribution of the concentrations of test samples reducing the signal by 50% in the artifact assay for a scintillation proximity assay. These 1412 samples were previously identified as inhibitory when tested at 10 µM in a radioligand binding activity screen in which ligand binding was indicated by an increased count rate. Each bar represents a 5-µM-wide bin. The 630 samples for which more than 100 µM was required to reach 50% signal reduction are not shown. high-throughput screen. Test samples exhibiting the types of interference that result in an apparent loss of activity would not have been selected for further analysis because they would appear to have lacked an inhibitory effect, whether or not they actually had one.
Because of the large scale of typical high-throughput screens (10 5   -10 6 test samples), we have not applied the method described in the Materials and Methods section to correct screening data for test sample interference during the initial single-point screening stage of high-throughput screens. Instead, the method has been applied at the subsequent concentration-response stage, when the potency of active test samples is measured (see below).
IC 50 measurement correction
To demonstrate the importance of correcting for interference caused by test samples in biochemical assays, it is instructive to compute the effect of the interference on measurements of test sample potency. For inhibitors, a common measurement is the concentration at which the activity of the target is reduced by 50% (IC 50 ). Consider an absorbance assay with a path length of 5 mm, an absorbance increase in the absence of inhibitor of 0.2 units, a test sample with an extinction coefficient at the monitored wavelength of 15 mM -1 ⋅cm -1 , and an IC 50 of 3 µM with a Hill slope of 1. Due to the absorbance of the test sample, the curve of percent inhibition versus test sample concentration would reach a maximum of 44% at 6.5 µM before decreasing again and would therefore be either uninterpretable or considered to be inactive due to the lack of a measurable IC 50 (Fig. 5) . With the correction procedure, concentrations up to 50 µM could be used to generate the IC 50 curve, with the correct IC 50 , before the extent of interference was as large as the signal, causing the data to be rejected. The same situation applies to fluorescent test samples in fluorescence-based assays.
The effect of a quenching test sample on the IC 50 measurement in a fluorescence intensity-based assay is shown for a theoretical example in Figure 6 . In this example, a test sample with an IC 50 of 100 µM appears to have an IC 50 of 8.45 µM due to a Stern-Volmer quenching constant (K sv ) of 0.1 µM -1 . The same situation occurs with absorption of light by test samples in fluorescence intensity-, luminescence-, and scintillationbased assays.
In an actual example of the application of our approach to correction of assay results for interference caused by test samples, IC 50 s were measured for a set of 379 test samples in a dual-emission wavelength ratio FRET assay. The excitation wavelength was 485 nm, and the emission wavelengths were 535 and 595 nm. The readout of the assay was the 595-nm/535-nm fluorescence ratio. To demonstrate the overall impact of the correction protocol, we computed IC 50 s with and without correction for interference. The 2 emission measurements were corrected separately before being combined to generate a fluorescence ratio. Interference-free IC 50 s were generated from the same assay plates with a high-performance liquid chromatography (HPLC) assay by separating the test samples from the macromolecular analytes using size exclusion chromatography in the presence of 6M urea. The distribution of the ratios of the interference-free IC 50 s from the HPLC assay to the corrected and uncorrected IC 50 s from the FRET assay is shown in Figure 7 . There was a pronounced leftward shift of the distribution of the ratios for corrected IC 50 s, with respect to the uncorrected IC 50 s, toward the ideal value of 1. This result 
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shows that correcting the FRET assay IC 50 s for interference substantially improved the agreement between the FRET assay IC 50 s and the interference-free IC 50 s measured by HPLC.
DISCUSSION
When measuring the effects of test samples on biochemical systems in high-throughput assays using multiwell plates, in which the test sample remains in the well during the measurement, interference with the measurement by the test samples frequently occurs. Interference by test samples can seriously affect the accuracy of the measurements. In this article, we have described a simple arithmetic approach that corrects well by well for several types of interference after quantifying it in a separate measurement. This method can be applied both to screening data, in which a single measurement is typically made with each test sample, and to measurements of potency, such as the IC 50 , in which measurements are made on a series of dilutions of the test sample.
Application of the correction method at the concentrationresponse stage of screening on apparently active test samples from such screens has demonstrated that a high percentage of samples interfere with detection at the primary screening concentration of 10 µM (Figs. 1-3) . The examples shown were from scintillation-, fluorescence intensity-, and absorbancebased assays. Simeonov et al. 2 investigated the fluorescence properties of a 70,000-sample screening collection and found, for example, that 0.17% of the samples were at least as brightly fluorescent as 10 nM fluorescein. This level of fluorescence interference could potentially result in hundreds of false positives in a high-throughput screen of a 1,000,000-sample library with an activity assay based on a decrease in fluorescence intensity or an increase in fluorescence polarization.
Using the correction method during the concentrationresponse stage allowed us to identify false positives caused by interfering test samples and remove them from further consideration, while sacrificing the ability to rescue false negatives from the screen. For smaller scale high-throughput screens, specifically high-concentration biochemical screening of fragment libraries, 1 which contain fewer than 20,000 test samples, the correction method is used at the initial single-point stage of screening as well as at the concentration-response stage.
Although the methodology for well-by-well correction of detection artifacts described here was not intended as a palliative for so-called plate patterns (i.e., systematic error resulting in differences in signal depending on the location in the assay plate), it may be used for that purpose. Because each well in the activity assay plate is corrected for differences from the baseline in the corresponding well of an identically arranged artifact assay plate (i.e., each test sample is in the same well in both plates), systematic plate pattern effects should also be reduced by the correction method. Other methods have been described that were designed specifically for correction of systematic errors in HTS but not correction for interference by test samples (see Makarenkov et al. 11 and references therein). Such methods do not use an artifact plate.
The use of continuous rather than endpoint assays can automatically correct for one type of assay interference-static test sample absorbance or fluorescence on continuous absorbanceor fluorescence intensity-based assays, respectively. Performing serial measurements of each well and calculating the difference subtracts the test sample signal without resorting to an artifact assay plate. Importantly, however, this approach does not correct for effects that reduce detection sensitivity. It is only suitable for use with continuous, not endpoint, assays, and it depends on the interference remaining unchanged during the time course of the measurement.
Other variations on the procedure described herein may be considered. For example, in a fluorescence intensity-based assay, it may be found that a predominant form of interference is for nonfluorescent test samples to enhance the fluorescence of the reporter. In that case, it would be better to apply a ratiometric 
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Uncorrected Corrected correction factor to the elevated fluorescence rather than a subtractive one. Earnshaw et al. 12 observed that quenching by test samples of Tb 3+ fluorescence was common and frequently substantial in time-resolved FRET (TR-FRET)-based assays. They identified quenching by adding the test sample to the assay without enzyme activity, then applied an empirically determined quench correction algorithm based on measurements made in 2 different fluorescence lifetime windows. The authors observed that quench correction markedly reduced the false-positive rate.
The methodology we have described is applicable to measurements using standard commercial plate readers that measure the bulk sample in the well. More sophisticated fluorescencebased measurements, including fluctuation and lifetime methods, are capable of distinguishing between populations of fluorescent molecules in a single well. Some of these methods, which require specialized instrumentation and analysis software, allow for identification and correction of fluorescence artifacts within a single well. 13 The propagation of measurement error should be considered when combining 2 measurements to generate a corrected measurement. If the measurements are of low precision, the reduction of the signal/noise ratio caused by the correction procedure may not be tolerable. This effect has not been a limitation in our hands, however. To ascertain the variation in both the activity assay and the artifact assay measurements, multiple plates of each could be prepared.
Instead of correcting the measurements used to determine IC 50 s, an alternative approach would be to compare the size of the artifactual signal-test sample concentration relationship to the IC 50 . An advantage of this alternative is that it would not introduce additional noise into the IC 50 measurement. In practice, however, this is an unsatisfactory approach for 2 reasons. First, there is no objective way to determine how close together the artifact signal and the IC 50 must be before the utility of the IC 50 comes into doubt. Second, as has been shown in Figures 5  and 6 , relatively small amounts of interference can cause substantial errors in the measurement of IC 50 .
When preparing to perform a high-throughput screen with an unfamiliar assay format, it would be advisable to determine in advance the most predominant forms of interference so that appropriate correction procedures can be employed. This can be done by subjecting a subset of the test samples to the artifact assay measurement, a common practice for high-throughput screen validation. In some cases, a useful additional measurement, requiring a replicate set of plates, would be to measure the signal from the test samples alone, without the addition of a baseline analyte. In the hypothetical example mentioned above of an assay in which enhancement of the reporter fluorescence is a common form of interference, the signal from the test samples alone would show whether the samples were themselves fluorescent.
The correction procedure can be validated experimentally for a particular assay by using substances known to interfere in particular ways but that do not inhibit the activity of the biochemical system of interest. For example, an absorbing or fluorescent substance or a fluorescence quencher can be added to the assay and artifact plates in various amounts. In addition, the concentration of the analyte that serves to generate the baseline in the artifact assay plate (B1) can be varied to establish the relationship between the accuracy of the correction procedure and the size of the artifact assay baseline.
A test sample may cause more than one type of interference at the same time. It is unlikely that the simple approach to artifact correction described here will accurately account for such complex phenomena. It is expected, however, that the corrected measurement will be closer to the true value than an uncorrected measurement. Individual interfering test samples could be examined in detail to characterize the nature of their interference. Because our use of the correction procedure has been with large numbers of test samples in high-throughput assays, however, we have not done this. A more productive approach has been to follow up the original high-throughput IC 50 measurements with additional measurements using a different detection technology, preferably including a chromatographic separation. The number of test samples from a high-throughput screen subjected to this secondary assay is usually much smaller than the original number after filtering based on IC 50 measurements. This process reduces the likelihood that false-positive test samples continue to be investigated. This shows that the measured intensity should be multiplied by a factor to generate the corrected intensity.
APPENDIX
(continued)
